Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Alphamab Oncology
The 2022 pricing negotiations for innovative drugs organized by China’s National Healthcare Security Administration have slashed prices of included products by 60% on average, a level mostly unchanged from the 2021 round, although 36% more novel medicines were covered.
As of October 2022, China's GloriaBio had reached less than 25% of the annual sales volume expected for its anti-PD-1 antibody zimberelimab and was set to miss its full-year target, forcing a CNY423m ($62m) impairment provision and illustrating how immuno-oncology fortunes can fluctuate in the country.
Four latecomers including Akeso and Henlius managed to record a combined $101m in immuno-oncology drug sales in China in the first half, while market leaders such as BeiGene and Innovent saw mixed results as competition between domestically-developed rivals continues to heat up.
A number of major Chinese pharma firms, including Simcere and Hansoh, brought in more revenues from innovative drugs than generics in the first half, a major stand-out from their domestic peers.
- Large Molecule
- Other Names / Subsidiaries
- Alphamab Biopharmaceuticals Co., Ltd.
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd.
- Suzhou Alphamab Co., Ltd.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.